nelfinavir has been researched along with HIV in 47 studies
*HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (21.28) | 18.2507 |
| 2000's | 34 (72.34) | 29.6817 |
| 2010's | 3 (6.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR | 1 |
| Furfine, ES; Hanlon, MH; Hazen, RJ; Miller, JF; Ray, JA; Robinson, L; Samano, V; Spaltenstein, A | 1 |
| Brieger, M; Furfine, ES; Hazen, RJ; Kaldor, I; Miller, JF; Reynolds, D; Sherrill, RG; Spaltenstein, A | 1 |
| Ami, E; Hamada, Y; Hayashi, Y; Hidaka, K; Kimura, T; Kiso, Y; Nakahara, K; Nakatani, S; Nguyen, JT; Sato, A | 1 |
| Barreca, ML; Benkestock, K; Chimirri, A; Christ, F; De Luca, L; Debyser, Z; Eneroth, A; Ferro, S; Hombrouck, A; Johansson, NG; Michiels, M; Noppe, W; Sahlberg, BL; Van Remoortel, B; Vrang, L; Witvrouw, M | 1 |
| Baptista, LPR; Branquinha, MH; Castilho, VVS; d'Avila-Levy, CM; Gonçalves, KCS; Guimarães, AC; Menna-Barreto, RFS; Rebello, KM; Sangenito, LS; Santos, ALS; Santos, HLC | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Krauchenco, S; Martins, NH; Polikarpov, I; Sanches, M | 1 |
| Asensi, V; Cartón, JA; Collazos, J | 1 |
| Ellis, GM; Frenkel, LM; Hitti, J; Huang, S | 1 |
| Biasin, M; Clerici, M; Di Pietro, M; Lo Caputo, S; Maserati, R; Mazzotta, F; Ravasi, G; Seminari, E; Trabattoni, D | 1 |
| Berenguer, J; Casas, E; Castro, A; de Mendoza, C; López-Calvo, S; Núńez, M; Podzamczer, D; Rosón, B; Rubio, A; Soriano, V; Valer, L | 1 |
| Piliero, P; Sanne, I; Schnittman, S; Squires, K; Thiry, A | 1 |
| Bergshoeff, AS; Burger, DM; Geelen, SP; Wolfs, TF | 1 |
| Bakshi, KK; Chen, J; Condra, JH; Danovich, RM; DiNubile, MJ; Graham, DJ; Haas, DW; Holder, DJ; Rhodes, RR; Saah, AJ; Shivaprakash, M | 1 |
| Calza, L; Chiodo, F; Manfredi, R | 1 |
| Bergshoeff, AS; Burger, DM; de Groot, R; Fraaij, PL; Geelen, SP; van Rossum, AM; Wolfs, TF | 1 |
| Bouvet, E; Chêne, G; Cottalorda, J; de Boever, CM; Journot, V; Le Moing, V; Leport, C; Peytavin, G; Préau, M; Raffi, F | 1 |
| Acosta, EP; Brundage, RC; Fletcher, CV; Gulick, RM; Haubrich, R; Jiang, H; Katzenstein, D | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Bond, SJ; Sarah Walker, A; White, IR | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Back, DJ; Cane, P; Chandler, B; Detsika, MG; Khoo, SH; Owen, A; Winstanley, C | 1 |
| Back, DJ; Cane, PA; Chandler, B; Detsika, M; Evans, S; Hartkoorn, RC; Khoo, SH; Owen, A | 1 |
| Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D | 1 |
| Baker, R; Brooks, JT; Hoffman, M; Moorman, A; Novak, R; Uy, J | 1 |
| Ahle, D; Bushnell, S; Chang, C; Collins, ML; Detmer, J; Fine, E; Ho, DD; Horn, T; Irvine, B; Kolberg, J; Shen, LP; Tyner, D; Urdea, MS; Zayati, C | 1 |
| Faulds, D; Jarvis, B | 1 |
| Jackson, RC | 1 |
| Butcher, D; Duong, P; Greene, J; Markson, L | 1 |
| Duncombe, C | 1 |
| Aladdin, H; Dickmeiss, E; Gerstoft, J; Hede, A; Jørgensen, LB; Katzenstein, TL; Nielsen, C; Nielsen, H | 1 |
| Adler, M; Cross, AP; Dunkle, LM; Elion, R; Kaul, S; Kelleher, T; Knupp, C | 1 |
| Atkinson, B; Isaacson, J; Knowles, M; Mazabel, E; Patick, AK | 1 |
| Arnedo, A; Gómez, CJ; Roca, B | 1 |
| Apuzzo, L; Deetz, C; Eshleman, SH; Fields, C; Flexner, C; Gallant, JE; Heath-Chiozzi, M; Jackson, JB; Lewis, RH; Raines, CP; Sun, E | 1 |
| Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R | 1 |
| Mascolini, M | 1 |
| Becker, MI; Harrigan, PR; Humar, A; Walmsley, SL; Zhang, M | 1 |
| Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L | 1 |
| Fitzgibbon, JE; Gaur, S; Janahi, M; John, JF; Walsman, SM; Whitley-Williams, P | 1 |
| Bartlett, JA; Bucy, RP; Fiscus, SA; Gryszowska, V; Miralles, GD; Ottinger, J; Pruitt, SK; Sevin, AD; Silberman, M | 1 |
3 review(s) available for nelfinavir and HIV
| Article | Year |
|---|---|
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Nelfinavir. A review of its therapeutic efficacy in HIV infection.
Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Drug Tolerance; HIV; HIV Infections; Humans; Nelfinavir | 1998 |
[Resistance to protease inhibitors].
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
11 trial(s) available for nelfinavir and HIV
| Article | Year |
|---|---|
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interferon-gamma; Interleukin-10; Interleukin-2; Male; Nelfinavir; Oxazines; Random Allocation; RNA, Messenger; Stavudine; Treatment Failure | 2002 |
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
Topics: Adult; Atazanavir Sulfate; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Nelfinavir; Oligopeptides; Pyridines; RNA, Viral; Stavudine; Time Factors; Viral Load | 2003 |
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Organophosphonates; Oxazines; Treatment Failure | 2003 |
Prospective comparison of first-line nelfinavir therapy versus nelfinavir introduction in rescue antiretroviral regimens.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infections; Nelfinavir; Prospective Studies; RNA, Viral; Salvage Therapy; Transcription Factors | 2003 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Sex Factors | 2004 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Female; Graft Rejection; Half-Life; Hepatitis C; HIV; HIV Infections; Humans; Liver Transplantation; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Tacrolimus; Viral Load | 2007 |
The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Topics: Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; RNA, Viral; Safety; Stavudine; Treatment Outcome; Viral Load | 1999 |
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Failure; Viral Load | 2001 |
Phase II/III Trials of Viracept start.
Topics: Anti-HIV Agents; Blood; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; Stavudine; Sulfonic Acids; Time Factors; Zidovudine | 1996 |
Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
Topics: Adolescent; Adult; CD4 Lymphocyte Count; Cyclophosphamide; DNA, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lymphoid Tissue; Male; Middle Aged; Monocytes; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Viral Load | 2002 |
33 other study(ies) available for nelfinavir and HIV
| Article | Year |
|---|---|
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Dogs; Drug Design; HIV; HIV Protease Inhibitors; Molecular Structure; Mutation; Protein Binding; Urea; Virus Replication | 1998 |
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
Topics: Animals; Anti-HIV Agents; Cell Line; Drug Resistance, Multiple, Viral; HIV; HIV Protease; HIV Protease Inhibitors; Humans; Molecular Structure; Mutation; Rats; Structure-Activity Relationship; Sulfonamides | 2004 |
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Topics: Animals; Anti-HIV Agents; Dogs; Drug Resistance, Multiple, Viral; HIV; HIV Protease Inhibitors; Inhibitory Concentration 50; Mutation; Rats; Structure-Activity Relationship; Virus Replication | 2005 |
Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.
Topics: Amides; Cell Line; Cysteine; HIV; HIV Protease Inhibitors; Humans; Models, Molecular; Phenylbutyrates; Thiazoles | 2007 |
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
Topics: Anti-HIV Agents; Caco-2 Cells; Cell Line, Tumor; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; HIV; HIV Integrase Inhibitors; Humans; Indoles; Integrases; Molecular Structure; Polymerase Chain Reaction; Viral Proteins; Virus Replication | 2008 |
Docking simulation between HIV peptidase inhibitors and Trypanosoma cruzi aspartyl peptidase.
Topics: Anti-HIV Agents; Aspartic Acid Proteases; Atazanavir Sulfate; Crystallography, X-Ray; Databases, Protein; Drug Repositioning; HIV; Molecular Docking Simulation; Nelfinavir; Peptide Hydrolases; Protease Inhibitors; Protein Conformation; Saccharomyces cerevisiae Proteins; Saquinavir; Trypanosoma cruzi | 2018 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
Effectiveness of commercial inhibitors against subtype F HIV-1 protease.
Topics: Amino Acid Sequence; Binding Sites; Drug Resistance, Viral; Enzyme Activation; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Microbial Viability; Molecular Sequence Data; Mutation; Nelfinavir; Polymorphism, Genetic; Ritonavir; Sequence Alignment | 2009 |
CD4 responses in the setting or suboptimal virological responses to antiretroviral therapy: features, outcomes, and associated factors.
Topics: Adult; CD4 Antigens; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Treatment Outcome; Viral Load | 2009 |
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Nelfinavir; Nevirapine; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Selection, Genetic | 2011 |
Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.
Topics: Adult; Drug Resistance; Female; Genes, Viral; Genotype; HIV; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV Seropositivity; Humans; Male; Middle Aged; Mutation; Nelfinavir | 2002 |
Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
Topics: Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Drug Interactions; HIV; HIV Infections; Humans; Infant; Male; Mycobacterium tuberculosis; Nelfinavir; Rifampin; Ritonavir; RNA, Viral; Tuberculosis, Pulmonary; Viral Load | 2003 |
Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
Topics: Adolescent; Body Surface Area; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Nelfinavir; Retrospective Studies; RNA, Viral | 2003 |
Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
Topics: Biotransformation; Cohort Studies; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; RNA, Viral; Time Factors; Treatment Failure; Viral Load | 2003 |
Instrumental variables and interactions in the causal analysis of a complex clinical trial.
Topics: Anti-HIV Agents; Child; Data Interpretation, Statistical; Female; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Models, Statistical; Nelfinavir; Patient Compliance; Randomized Controlled Trials as Topic; RNA, Viral | 2007 |
Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification.
Topics: Amino Acid Substitution; Drug Resistance, Viral; HIV; HIV Infections; Humans; Mutation; Nelfinavir; Polymerase Chain Reaction; Sensitivity and Specificity | 2007 |
Effect of transporter modulation on the emergence of nelfinavir resistance in vitro.
Topics: Cell Line; Cytopathogenic Effect, Viral; DNA Mutational Analysis; Drug Resistance, Viral; HIV; HIV Protease; HIV Protease Inhibitors; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Mutation; Nelfinavir; Verapamil; Virus Replication | 2007 |
HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
Topics: Adult; Algorithms; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Viral Load | 2007 |
Anti-HIV effects of Viracept persist during long periods of combination therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Safety; Sulfonic Acids | 1997 |
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.
Topics: Adenosine; Anti-HIV Agents; Cytidine; DNA; DNA, Viral; Drug Therapy, Combination; Guanosine; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Nelfinavir; Nucleic Acid Hybridization; RNA, Viral; Sulfonic Acids; Zidovudine | 1997 |
A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity.
Topics: Anti-HIV Agents; CD4-CD8 Ratio; Dose-Response Relationship, Drug; Drug Resistance, Microbial; HIV; HIV Infections; Humans; Models, Theoretical; Nelfinavir; Zidovudine | 1997 |
Virologic response associated with a change in protease inhibitor therapy.
Topics: HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; RNA, Viral; Treatment Outcome | 2000 |
Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lipodystrophy; Nelfinavir; Prospective Studies | 2000 |
Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis.
Topics: Adolescent; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Transfusion Reaction; Zidovudine | 2000 |
Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Zidovudine | 2000 |
Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Logistic Models; Male; Nelfinavir; Patient Compliance; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Statistics, Nonparametric; Stavudine; Substance Abuse, Intravenous | 2000 |
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.
Topics: Adult; Chromatography, High Pressure Liquid; Cohort Studies; DNA, Viral; Female; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; Sequence Analysis, DNA; Viral Load | 2000 |
Protease inhibitor trials moving to next phase.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication | 1995 |
Agouron protease inhibitor.
Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 1995 |
Closing the circle on HIV--or not.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Nelfinavir; Prognosis; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Genotype; HIV; HIV Infections; Humans; Male; Nelfinavir; RNA, Viral; Salvage Therapy | 2001 |
Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Nelfinavir; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral | 2001 |
Nelfinavir (Viracept).
Topics: Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Practice Guidelines as Topic | 2000 |